The following commentary by our CEO, Dr. Frank Borriello, is about the current challenges and limitations of immune checkpoint inhibitor (ICI) combinations in cancer treatment. Dr. Borriello touches on the need for a strategic shift in approach. This article – published in Endpoints – hi...
Category: Opinion
-
March 10, 2025
Beyond a Single Trial: Rethinking Immune Checkpoint Inhibitor Combinations
-
March 6, 2025
AlphaFold’s Breakthrough in Protein Structure Prediction: Lessons for Cell Therapy
Opinion on the importance of first developing robust datasets for future AI efforts.
-
January 23, 2025
George Yancopoulos says hype around AI has outpaced reality
Alloplex CEO agrees, says machine learning and AI being conflated.
-
July 31, 2024
‘Gen X and millennials at higher cancer risk’, Washington Post article
Dr. Borriello speaks of collective responsibility amongst all involved in developing drugs to combat cancer.
-
July 28, 2024
Groupthink in Alzheimer’s Research limits the range of ideas that are explored effectively
Dr. Borriello shares his thoughts on an opinion piece that appeared in the New York Times.
-
April 4, 2024
Smaller pharmaceutical startups are the real drivers of drug development
Alloplex CEO comments on Washington Post article and data that shows 'Big Pharma's high prices don't drive innovation'.